Trials / Completed
CompletedNCT01933763
An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Study to assess the safety and tolerability of ascending single-doses of REGN1193 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN1193 | |
| OTHER | Placebo |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2013-09-02
- Last updated
- 2015-03-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01933763. Inclusion in this directory is not an endorsement.